Thousand Oaks biotech Atara Biotherapeutics reported a 71 percent increase in research and development spending for its first quarter, sending its net losses soaring nearly 60 percent to $66 million. The news drove shares down more than 20 percent to $27.01 as of 11 a.m. March 9, though net losses of $1.44 per share came…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
